LOXO-305: Next-gen BTK inhibitor safe and effective in B-cell malignanciesDecember 20, 2019Mantle Cell LymphomaB Cell LymphomaCLL
Survival data reported from largest CAR T trial in B-cell lymphomaDecember 20, 2019B Cell LymphomaDLBCLIndolent Lymphoma
Some MCL patients can safely stop venetoclax-ibrutinib, study suggestsDecember 14, 2019Mantle Cell LymphomaB Cell Lymphoma
KTE-X19 produces highest response rate in MCL subgroupDecember 14, 2019Mantle Cell LymphomaB Cell Lymphoma
An off-the-shelf drug to rival CAR T cells: ‘very exciting’December 13, 2019B Cell LymphomaCellular Therapy
Orelabrutinib could be ‘preferred’ BTK inhibitor for MCLDecember 12, 2019Mantle Cell LymphomaB Cell Lymphoma
Efficacy of postvenetoclax therapy may depend on prior agent exposure in CLLDecember 10, 2019CLLB Cell Lymphoma
Off-the-shelf cellular therapy shows promise in the labDecember 8, 2019B Cell LymphomaCLLCellular Therapy
Newly identified genetic changes contribute to transformation of follicular lymphomaDecember 7, 2019B Cell Lymphoma
Acalabrutinib may outperform other targeted therapies in MCLDecember 4, 2019Mantle Cell LymphomaB Cell Lymphoma
Frontline ibrutinib saves money over chemoimmunotherapyNovember 20, 2019CLLBusiness of MedicineB Cell Lymphoma
